PL2740793T3 - Kompozycja leku do leczenia i/lub zapobiegania nowotworowi - Google Patents
Kompozycja leku do leczenia i/lub zapobiegania nowotworowiInfo
- Publication number
- PL2740793T3 PL2740793T3 PL12819759T PL12819759T PL2740793T3 PL 2740793 T3 PL2740793 T3 PL 2740793T3 PL 12819759 T PL12819759 T PL 12819759T PL 12819759 T PL12819759 T PL 12819759T PL 2740793 T3 PL2740793 T3 PL 2740793T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- cancer treatment
- drug composition
- drug
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171332 | 2011-08-04 | ||
| PCT/JP2012/069857 WO2013018892A1 (ja) | 2011-08-04 | 2012-08-03 | 癌の治療及び／又は予防用医薬組成物 |
| EP12819759.7A EP2740793B1 (en) | 2011-08-04 | 2012-08-03 | Drug composition for cancer treatment and/or prevention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2740793T3 true PL2740793T3 (pl) | 2018-04-30 |
Family
ID=47629406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12819759T PL2740793T3 (pl) | 2011-08-04 | 2012-08-03 | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9181334B2 (pl) |
| EP (1) | EP2740793B1 (pl) |
| JP (1) | JP6015448B2 (pl) |
| KR (1) | KR101968498B1 (pl) |
| CN (1) | CN103717738B (pl) |
| AU (1) | AU2012290955B2 (pl) |
| BR (1) | BR112014002621B1 (pl) |
| CA (1) | CA2844038C (pl) |
| DK (1) | DK2740793T3 (pl) |
| ES (1) | ES2660115T3 (pl) |
| HU (1) | HUE035689T2 (pl) |
| MX (1) | MX348579B (pl) |
| PL (1) | PL2740793T3 (pl) |
| PT (1) | PT2740793T (pl) |
| RU (1) | RU2624049C2 (pl) |
| TR (1) | TR201802089T4 (pl) |
| WO (1) | WO2013018892A1 (pl) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2322221E (pt) | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| KR101805520B1 (ko) * | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| PT2741085T (pt) * | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| WO2013018886A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP2818483B1 (en) | 2012-02-21 | 2017-08-02 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| CA2869123C (en) | 2012-03-30 | 2021-03-16 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer |
| CN104220095B (zh) | 2012-03-30 | 2016-09-07 | 东丽株式会社 | 肝癌的治疗和/或预防用药物组合物 |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| EP2876446B1 (en) | 2012-07-19 | 2018-12-26 | Toray Industries, Inc. | Method for detecting cancer |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| PL3587448T3 (pl) * | 2013-03-15 | 2021-11-29 | Xencor, Inc. | Białka heterodimeryczne |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3031826B1 (en) | 2013-08-09 | 2018-10-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| MX2018016265A (es) | 2016-06-28 | 2019-07-04 | Xencor Inc | Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina. |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| EP3533466A4 (en) | 2016-10-28 | 2020-06-10 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION |
| KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
| BR112020019935A2 (pt) | 2018-03-30 | 2021-01-26 | Toray Industries, Inc. | medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| AU2020232605A1 (en) | 2019-03-01 | 2021-10-21 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CA3142887A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| WO2021067242A1 (en) | 2019-09-30 | 2021-04-08 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| TWI857167B (zh) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
| US20230139178A1 (en) * | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| BR112022018166A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| US20230140155A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20220152318A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| BR112022018161A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
| CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| US20230263903A1 (en) | 2020-08-13 | 2023-08-24 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| JP7773528B2 (ja) | 2020-08-19 | 2025-11-19 | ゼンコア インコーポレイテッド | 抗ｃｄ２８組成物 |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| BR112023026992A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
| MX2023014498A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| JPWO2023008461A1 (pl) | 2021-07-27 | 2023-02-02 | ||
| CA3227698A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| US20250367307A1 (en) | 2022-06-30 | 2025-12-04 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20250052364A (ko) | 2022-08-24 | 2025-04-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2024043252A1 (pl) | 2022-08-24 | 2024-02-29 | ||
| KR20250054778A (ko) | 2022-08-30 | 2025-04-23 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20250118852A (ko) | 2022-12-23 | 2025-08-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| JP2026506037A (ja) | 2023-02-14 | 2026-02-20 | ボルト バイオセラピューティクス、インコーポレーテッド | アザベンズアゼピンイムノコンジュゲート及びその使用 |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| AU2024242849A1 (en) | 2023-03-28 | 2025-09-25 | Toray Industries, Inc. | Method for detecting cell membrane protein |
| JPWO2024204685A1 (pl) | 2023-03-31 | 2024-10-03 | ||
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
| WO2026055185A1 (en) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Sting agonist immunoconjugates and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| KR20010083111A (ko) | 1998-07-14 | 2001-08-31 | 길리스 스티브 | 전립선암의 치료 및 진단을 위한 조성물 및 방법 |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| HK1045332A1 (zh) | 1999-04-02 | 2002-11-22 | Corixa Corporation | 用於治療和診斷肺癌的化合物及其使用方法 |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| EP2003196A3 (en) | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) * | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| NZ560976A (en) | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007095186A2 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| BRPI0911925B8 (pt) * | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| PT2322221E (pt) | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| BRPI0912462B1 (pt) | 2008-08-05 | 2022-03-22 | Toray Industries, Inc | Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante |
| AU2010285265B2 (en) | 2009-08-19 | 2015-05-21 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in FFPE material |
| US8642292B2 (en) | 2009-09-22 | 2014-02-04 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| CA2788716C (en) | 2010-02-04 | 2019-06-18 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| BR112012018943A8 (pt) | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| PL2532364T3 (pl) | 2010-02-04 | 2016-11-30 | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
| US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| PT2741085T (pt) | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| WO2013018886A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| CA2869123C (en) | 2012-03-30 | 2021-03-16 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer |
| CN104220095B (zh) | 2012-03-30 | 2016-09-07 | 东丽株式会社 | 肝癌的治疗和/或预防用药物组合物 |
-
2012
- 2012-08-03 RU RU2014108042A patent/RU2624049C2/ru active
- 2012-08-03 PT PT128197597T patent/PT2740793T/pt unknown
- 2012-08-03 BR BR112014002621-1A patent/BR112014002621B1/pt active IP Right Grant
- 2012-08-03 ES ES12819759.7T patent/ES2660115T3/es active Active
- 2012-08-03 HU HUE12819759A patent/HUE035689T2/en unknown
- 2012-08-03 JP JP2012543825A patent/JP6015448B2/ja active Active
- 2012-08-03 AU AU2012290955A patent/AU2012290955B2/en active Active
- 2012-08-03 MX MX2014001373A patent/MX348579B/es active IP Right Grant
- 2012-08-03 WO PCT/JP2012/069857 patent/WO2013018892A1/ja not_active Ceased
- 2012-08-03 US US14/236,812 patent/US9181334B2/en active Active
- 2012-08-03 KR KR1020147005882A patent/KR101968498B1/ko active Active
- 2012-08-03 EP EP12819759.7A patent/EP2740793B1/en active Active
- 2012-08-03 DK DK12819759.7T patent/DK2740793T3/en active
- 2012-08-03 CA CA2844038A patent/CA2844038C/en active Active
- 2012-08-03 CN CN201280038466.XA patent/CN103717738B/zh active Active
- 2012-08-03 TR TR2018/02089T patent/TR201802089T4/tr unknown
- 2012-08-03 PL PL12819759T patent/PL2740793T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2740793A1 (en) | 2014-06-11 |
| TR201802089T4 (tr) | 2018-03-21 |
| JPWO2013018892A1 (ja) | 2015-03-05 |
| WO2013018892A1 (ja) | 2013-02-07 |
| BR112014002621B1 (pt) | 2022-09-20 |
| RU2624049C2 (ru) | 2017-06-30 |
| JP6015448B2 (ja) | 2016-10-26 |
| HUE035689T2 (en) | 2018-05-28 |
| US9181334B2 (en) | 2015-11-10 |
| CN103717738A (zh) | 2014-04-09 |
| KR101968498B1 (ko) | 2019-04-12 |
| DK2740793T3 (en) | 2018-01-22 |
| CA2844038C (en) | 2019-05-07 |
| BR112014002621A2 (pt) | 2017-12-12 |
| KR20140054186A (ko) | 2014-05-08 |
| EP2740793B1 (en) | 2017-11-29 |
| MX2014001373A (es) | 2014-05-21 |
| PT2740793T (pt) | 2018-02-23 |
| RU2014108042A (ru) | 2015-09-10 |
| CN103717738B (zh) | 2015-07-15 |
| EP2740793A4 (en) | 2015-04-01 |
| AU2012290955A1 (en) | 2014-03-20 |
| MX348579B (es) | 2017-06-20 |
| US20140199311A1 (en) | 2014-07-17 |
| CA2844038A1 (en) | 2013-02-07 |
| ES2660115T3 (es) | 2018-03-20 |
| AU2012290955B2 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| HUE046788T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
| PT2740489T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático | |
| PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
| HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
| PT2832365T (pt) | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático | |
| PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740794T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów | |
| PL2532367T3 (pl) | Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu | |
| PT2818482T (pt) | Composição farmacêutica para o tratamento de cancro | |
| PT2824114T (pt) | Composição farmacêutica para o tratamento do cancro | |
| IL225471A0 (en) | Preparations and methods for the prevention and treatment of cancer | |
| PT3031826T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| PL2663318T3 (pl) | Kompozycja farmaceutyczna do leczenia raka | |
| EP2902027A4 (en) | ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer | |
| AU2011211693B2 (en) | Pharmaceutical composition for treating and/or preventing cancer |